drugset
drugset / Trial / NCT00660426

Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors

NCT00660426 ↗

Phase 1 Completed 30 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Dose escalation of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.

Timeline

Start
2005-03
Primary completion
2006-10
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 600 mg/m2 Oral
Subject Capecitabine Small molecule 800 mg/m2 Oral
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 100 mg/m2 Intravenous

Indications

digestive system cancer